selected scholarly activity
-
books
-
chapters
- Cancer prevention and control as part of universal healthcare coverage: Implications for cervical cancer for the world health organization 2017 country capacity survey. 159-182. 2020
- Diagnosis and management of vaginal intraepithelial neoplasia. 63-96. 2016
- Implementing a cervical cancer screening program in low and middle income countries. 269-288. 2015
- The epidemiology of endometrial cancer. 1-29. 2014
- Planning and implementation of a cervical cancer screening program. 53-76. 2013
- Quality indicators for the practice of colposcopy in the screening and prevention of cervical cancer. 111-125. 2013
- Telemedicine in cervical screening. 41-52. 2013
- Screening for Cervical Cancer in Low-Resource Countries. 99-123. 2013
- Breaking bad news while keeping hope alive in women with ovarian cancer. 113-130. 2012
- Informatics and Ovarian Cancer Care. 185-261. 2009
- Preventing cervical cancer worldwide. 49-64. 2007
-
conferences
- Low-grade serous carcinoma (LGSC): A Canadian multicenter review of practice patterns and patient outcomes. Gynecologic Oncology. 36-45. 2020
- Molecular Signature of Aggressive Low Grade Endometrioid Endometrial Adenocarcinomas. Modern Pathology. 2019
- Molecular Signature of Aggressive Low Grade Endometrioid Endometrial Adenocarcinomas. Laboratory Investigation. 2019
- Negotiating and Navigating Access to Refugees and Residents While Researching Palliative Care in Humanitarian Crisis Situations: Results from 4 Case Studies. Journal of Pain and Symptom Management. e28-e28. 2018
- ‘Nothing in the World Can Serve Those People Like Palliative Care': Results from a Qualitative Study on Palliative Care for Refugees in Jordan and Rwanda. Journal of Pain and Symptom Management. e24-e24. 2018
- "There is no time for these patients": ethics, obstacles and palliative care in humanitarian settings. European Journal of Public Health. 187-187. 2018
- Incidence of Venous Thromboembolic Events Following Major Pelvic and Abdominal Surgery for Cancer. Annals of Surgical Oncology. S26-S26. 2017
- Incidence of venous thromboembolic events following major pelvic and abdominal surgery for cancer.. Journal of Clinical Oncology. 2017
- D08-C The Place of Palliative Care in Humanitarian Response. Journal of Pain and Symptom Management. e34-e35. 2016
- The Pathologic and Treatment Factors Associated With Recurrence in Stage IA Serous Adenocarcinoma of the Uterus. International Journal of Radiation Oncology Biology Physics. E315-E315. 2016
- Comparing cervical cancer stage at diagnosis in immigrant women and long-term residents.. Journal of Clinical Oncology. e18054-e18054. 2016
- Pathway map development as an approach to identifying priority areas for quality improvement in Ontario.. Journal of Clinical Oncology. 108-108. 2016
- The role of PET-CT in treatment decision making for women with locally advanced cervical cancer.. Journal of Clinical Oncology. 5523-5523. 2015
- UNDIFFERENTIATED ENDOMETRIAL CANCER, A DIFFERENT ENTITY WITH AN AGGRESSIVE BEHAVIOR. International Journal of Gynecological Cancer. 69-69. 2015
- DOES GROIN NODE DISSECTION IN VULVAR CANCER DECREASE THE RISK OF GROIN RECURRENCE?. International Journal of Gynecological Cancer. 1606-1606. 2014
- TIME SERIES ANALYSIS OF GENETICS CONSULTATION FOR PATIENTS WITH SEROUS PELVIC CARCINOMA. International Journal of Gynecological Cancer. 185-186. 2014
- Stereotactic Ablative Radiation Therapy for Gynecological Malignancies in the Oligometastatic Setting. International Journal of Radiation Oncology Biology Physics. S908-S908. 2014
- Impact of Wait Times on Survival for Women With Uterine Cancer. Obstetrical and Gynecological Survey. 143-144. 2014
- HPV Genotyping in Vulvar Squamous Cell Carcinoma: Comparison of a Luminex-Based Assay vs Linear Array. Modern Pathology. 305A-305A. 2014
- HPV Genotyping in Vulvar Squamous Cell Carcinoma: Comparison of a Luminex-Based Assay vs Linear Array. Laboratory Investigation. 305A-305A. 2014
- A multicenter open-label phase II study of the efficacy and safety of ganitumab (AMG 479), a fully human monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-1R) as second-line therapy in patients with recurrent platinum-sensitive ovarian cancer. Journal of Clinical Oncology. 2013
- Impact of wait times on survival of women with uterine cancer.. Journal of Clinical Oncology. 2013
- Population Study of Uterine Leiomyosarcoma Incidence, Mortality and Survival. Modern Pathology. 287A-287A. 2013
- Population Study of Uterine Leiomyosarcoma Incidence, Mortality and Survival. Laboratory Investigation. 287A-287A. 2013
- Western Clinical Health Ethics: How Well Do They Travel to Humanitarian Contexts?. DILEMMAS, CHALLENGES, AND ETHICS OF HUMANITARIAN ACTION: REFLECTIONS ON MEDECINS SANS FRONTIERES' PERCEPTION PROJECT. 73-88. 2012
- Quality of Life in the ICON7 GCIG Phase III Randomised Clinical Trial. European Journal of Cancer. 12-12. 2011
- Phase II study of oral ridaforolimus in patients with metastatic and/or locally advanced recurrent endometrial cancer: NCIC CTG IND 192.. Journal of Clinical Oncology. 2011
- Implementation of surgical treatment for early-stage cervical cancer by Kenyan gynecologists in western Kenya. Gynecologic Oncology. S108-S108. 2011
- End-of-Life Care for Women with Gynecologic Cancers. Journal of Palliative Care. 249-249. 2010
- A randomized, double-blind, placebo-controlled phase II study of the efficacy and safety of farletuzumab (MORAb-003) in combination with weekly paclitaxel in subjects with platinum-resistant or refractory relapsed ovarian cancer.. Journal of Clinical Oncology. TPS255-TPS255. 2010
- Can elderly patients with recurrent ovarian cancer (ROC) be treated with a platinum-based doublet? Results from the CALYPSO trial.. Journal of Clinical Oncology. 5031-5031. 2010
- Temsirolimus (TEM) in endometrial cancer: Predictors of response and progression.. Journal of Clinical Oncology. 3090-3090. 2010
- 18LBA A GCIG randomized phase III study of carboplatin (C) & pegylated liposomal doxorubicin (PLD) (C-D) vs carboplatin (C) & paclitaxel (P) (C-P): CALYPSO results in partially platinum-sensitive ovarian cancer (OC) patients. European Journal of Cancer, Supplement. 11-11. 2009
- Dalteparin low molecular weight heparin (LMWH) in ovarian cancer: A phase II randomized study. Journal of Clinical Oncology. 2009
- Differences in uptake of postoperative adjuvant chemotherapy for lung cancer: Results from the Project for an Ontario Women's Health Evidence-Based Report Card (POWER) study. Journal of Clinical Oncology. 2009
- Importance of stratification when measuring quality of care: Results from the Project for an Ontario Women's Health Evidence-Based Report Card (POWER) study. Journal of Clinical Oncology. 2009
- Combined p53 and p16 Expression Is Useful To Distinguish between Endometrial Serous and Endometrioid Carcinomas. Laboratory Investigation. 239A-240A. 2009
- Combined p53 and p16 Expression Is Useful To Distinguish between Endometrial Serous and Endometrioid Carcinomas. Modern Pathology. 239A-240A. 2009
- A phase II study of temsirolimus (CCI-779) in patients with metastatic and/or locally advanced recurrent endometrial cancer previously treated with chemotherapy: NCIC CTG IND 160b. Journal of Clinical Oncology. 5516-5516. 2008
- Sex, income and age-related differences in colorectal cancer care: results from the Project for an Ontario Women's Health Evidence-based Report Card (POWER) study. Journal of Clinical Oncology. 6509-6509. 2008
- Sorafenib (SOR) in patients (pts) with advanced/recurrent uterine carcinoma (UCA) or carcinosarcoma (CS): A phase II trial of the University of Chicago, PMH, and California Phase II Consortia. Journal of Clinical Oncology. 2008
- Immunolocalization of neurotrophin receptors tyrosine kinase receptors in Endometriosis Associated Ovarian Cancer (EAOC). Virchows Archiv. S81-S81. 2008
- Treating vulvar cancer in the new millennium: Are patients receiving optimal care?. Gynecologic Oncology. 71-75. 2008
- Learned participation: Women's perceptions about treatment decision making in recurrent ovarian cancer. Gynecologic Oncology. S62-S63. 2008
- Patterns of surgical care for gynecologic cancers in Ontario. Gynecologic Oncology. S37-S38. 2008
- CA-125 response as a marker of clinical benefit in patients with recurrent ovarian cancer treated with gemcitabine and sorafenib-A trial of the PMH Phase II Consortium. Journal of Clinical Oncology. 2007
- Use of systemic therapy in women with recurrent ovarian cancer-Development of a national clinical practice guideline. Journal of Clinical Oncology. 2007
- Molecular correlates associated with a phase II study of temsirolimus (CCI-779) in patients with metastatic or recurrent endometrial cancer - NCICIND 160.. Journal of Clinical Oncology. 121S-121S. 2006
- Phase II study of sorafenib (BAY 43-9006) in combination with gemcitabine in recurrent epithelial ovarian cancer: A PMH phase II consortium trial.. Journal of Clinical Oncology. 276S-276S. 2006
- The rapid uptake of concurrent chemotherapy for cervix cancer patients treated with curative radiation. International Journal of Radiation Oncology Biology Physics. 1389-1394. 2006
- A phase II study of temsirolimus (CCI-779) in patients with metastatic and/or locally recurrent endometrial cancer - NCICCTG IND 160.. Clinical Cancer Research. 9099S-9099S. 2005
- A Phase II study of Temsirolimus (CCI-779) in patients with metastatic and/or recurrent endometrial cancer - NCICCTG IND 160. European Journal of Cancer, Supplement. 261-261. 2005
- The rapid uptake of concurrent chemotherapy for cervix cancer patients treated with curative radiation. European Journal of Cancer, Supplement. 277-277. 2005
- Phase II multicenter open-label study of carboplatin and pegylated liposomal doxorubicin in uterine and cervical malignancies. International Journal of Gynecological Cancer. 799-806. 2005
- A multicenter, phase II study of cisplatin, irinotecan and epirubicin (PIE) administered every 3 weeks in patients with unresectable, locally advanced/metastatic cervical carcinoma.. Journal of Clinical Oncology. 480S-480S. 2005
- A multicenter, phase II study of cisplatin, irinotecan and epirubicin (PIE) administered every 3 weeks in patients with unresectable, locally advanced/metastatic cervical carcinoma. Annals of Oncology. 296-297. 2005
- Phase II study of erlotinib (OSI 774) in women with recurrent or metastatic endometrial cancer: NCICCTG IND-148.. Journal of Clinical Oncology. 453S-453S. 2004
- Phase II study of erlotinib (Tarceva, OSI774) in women with recurrent or metastatic endometrial cancer - NCICIND 148.. Clinical Cancer Research. 6094S-6094S. 2003
- Phase II study of c-raf kinase antisense oligonucleotide ISIS 5132 in patients (pts) with recurrent ovarian cancer - NCICIND.116.. Clinical Cancer Research. 4572S-4572S. 2000
- A study to determine the genetic basis of uterine papillary serous adenocarcinoma.. American Journal of Human Genetics. 86-86. 2000
- Assessment of cytologic follow-up as the recommended management for patients with atypical squamous cells of undetermined significance or low grade squamous intraepithelial lesions. Cancer. 5-10. 1998
- Assessment of cytologic follow up hs the recommended management for patients with ASCUS/LSIL. Laboratory Investigation. 162-162. 1997
- Evaluation of Hybrid Capture HPV testing as an aid to the management of colposcopy patients. Laboratory Investigation. 203-203. 1997
- The utility of hybrid capture HPV testing as an adjunct to follow up of patients with ASCUS/LSIL Pap smears. Laboratory Investigation. 163-163. 1997
-
journal articles
- Curriculum mapping evaluation of a Tyler model designed physiotherapy curriculum of the Baptist institute of health science in Cameroon. Cogent Education. 11. 2024
- Safety of vaginal surgery for early-stage cervical cancer: A retrospective multicenter cohort study. European Journal of Surgical Oncology. 50:108518-108518. 2024
- Mother-Child Approach to Cervical Cancer Prevention in a Low Resource Setting: The Cameroon Baptist Convention Health Services Story.. Current Oncology. 31:3227-3238. 2024
- Evaluating equity of access and predictors of minimally invasive hysterectomy for endometrial and cervical cancer from 2000 to 2017 in Ontario, Canada: A population‐based cohort study. Journal of Surgical Oncology. 129:392-402. 2024
- The life they now live: role of missionary hospitals in Sub Saharan Africa. Christian Journal for Global Health. 11:193-197. 2024
- Perceptions of Cancer in Parents of Adolescent Daughters in Northwest Cameroon. Current Oncology. 30:7167-7177. 2023
- A Double-blinded, Randomized Trial Comparing Surgeon-Administered Transversus Abdominis Plane Block With Placebo After Midline Laparotomy in Gynecologic Oncology Surgery. Obstetrical and Gynecological Survey. 78:404-405. 2023
- Surgical margin status in relation to surgical approach in the management of early-stage cervical Cancer: A Canadian cervical Cancer collaborative (4C) study. Gynecologic Oncology. 174:21-27. 2023
- A double-blinded, randomized trial comparing surgeon-administered transversus abdominis plane block with placebo after midline laparotomy in gynecologic oncology surgery. American Journal of Obstetrics and Gynecology. 228:553.e1-553.e8. 2023
- Oncologic Outcomes of Surgically Treated Cervical Cancer with No Residual Disease on Hysterectomy Specimen: A 4C (Canadian Cervical Cancer Collaborative) Working Group Study. Current Oncology. 30:1977-1985. 2023
- Aid when ‘there is nothing left to offer’: Experiences of palliative care and palliative care needs in humanitarian crises. PLOS Global Public Health. 3:e0001306-e0001306. 2023
- Disparities in the survival of endometrial cancer patients in a public healthcare system: A population-based cohort study. Gynecologic Oncology. 167:532-539. 2022
- Variability in endometrial carcinoma pathology practice: opportunities for improvement with molecular classification. Modern Pathology. 35:1974-1982. 2022
- Assessing knowledge, attitudes and belief toward HPV vaccination of parents with children aged 9–14 years in rural communities of Northwest Cameroon: a qualitative study. BMJ Open. 12:e068212-e068212. 2022
- Corrigendum to “Low-grade serous carcinoma (LGSC): A Canadian multicenter review of practice patterns and patient outcomes” [Gynecologic Oncology, Volume 157, Issue 1, April 2020, Pages 36–45]. Gynecologic Oncology. 167:399-399. 2022
- Development, Implementation, and Evaluation of a Distance Learning and Telementoring Program for Cervical Cancer Prevention in Cameroon. JAMA network open. 5:e2240801-e2240801. 2022
- Comparison of outcomes between abdominal, minimally invasive and combined vaginal-laparoscopic hysterectomy in patients with stage IAI/IA2 cervical cancer: 4C (Canadian Cervical Cancer Collaborative) study. Gynecologic Oncology. 166:230-235. 2022
- Study protocol for assessing knowledge, attitudes and belief towards HPV vaccination of parents with children aged 9–14 years in rural communities of North West Cameroon: a qualitative study. BMJ Open. 12:e062556-e062556. 2022
- Comparison of CINtec PLUS cytology and cobas HPV test for triaging Canadian patients with LSIL cytology referred to colposcopy: A two-year prospective study. Cancer Biomarkers. 34:347-358. 2022
- The impact of preoperative imaging on wait times, surgical approach and overall survival in endometrioid endometrial cancers. Gynecologic Oncology. 165:317-322. 2022
- Estrogen receptor-positive adenocarcinoma of the cervix presenting during pregnancy: Two case reports and review of the literature. Gynecologic Oncology Reports. 39:100916-100916. 2022
- Neoadjuvant and Adjuvant Systemic Therapy for Newly Diagnosed Stage II–IV Epithelial Ovary, Fallopian Tube, or Primary Peritoneal Carcinoma: A Practice Guideline. Current Oncology. 29:231-242. 2022
- A case analysis of partnered research on palliative care for refugees in Jordan and Rwanda. Conflict and Health. 15:2. 2021
- Comparison of Alinity m HPV and cobas HPV assays on cervical specimens in diverse storage media. Tumour Virus Research. 12:200224-200224. 2021
- Risk reduction strategies for BRCA1/2 hereditary ovarian cancer syndromes: a clinical practice guideline. Hereditary Cancer in Clinical Practice. 19:39. 2021
- Consolidation or maintenance systemic therapy for newly diagnosed stage II, III, or IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma: A systematic review. Critical Reviews in Oncology/Hematology. 162:103336-103336. 2021
- Corrigendum to CINtec PLUS and cobas HPV testing for triaging Canadian women referred to colposcopy with a history of low-grade squamous intraepithelial lesion: Baseline findings [Papillomavirus Res. 10 (2020) 100206]. Tumour Virus Research. 11:200215-200215. 2021
- Neoadjuvant and adjuvant systemic therapy for newly diagnosed stage II- IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma: A systematic review. Critical Reviews in Oncology/Hematology. 162:103324-103324. 2021
- The use of imaging in endometrial cancer prior to potential surgery: Are guidelines being followed?. Gynecologic Oncology. 161:361-366. 2021
- A pneumococcal pneumonia and influenza vaccination quality improvement program for women receiving chemotherapy for gynecologic cancers at a major tertiary cancer Centre. Gynecologic Oncology. 161:236-243. 2021
- An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline: Consolidation or Maintenance Systemic Therapy for Newly Diagnosed Stage II, III, or IV Epithelial Ovary, Fallopian Tube, or Primary Peritoneal Carcinoma. Current Oncology. 28:1114-1124. 2021
- Thirty‐day outcomes after gynecologic oncology surgery: A single‐center experience of enhanced recovery after surgery pathways. Acta Obstetricia et Gynecologica Scandinavica. 100:353-361. 2021
- CINtec PLUS and cobas HPV testing for triaging Canadian women referred to colposcopy with a history of low-grade squamous intraepithelial lesion: Baseline findings. Tumour Virus Research. 10:100206-100206. 2020
- Disparities in surgical management of endometrial cancers in a public healthcare system: A question of equity. Gynecologic Oncology. 159:387-393. 2020
- How to reduce the impact of cervical cancer worldwide: Gaps and priority areas identified through the essential cancer and primary care packages: An analysis of effective interventions. Cancer. 126:4697-4705. 2020
- Endometrial cancer presentation is associated with social determinants of health in a public healthcare system: A population-based cohort study. Gynecologic Oncology. 158:130-136. 2020
- Routine Imaging or No Routine Imaging, Is That the Question?. Journal of the National Comprehensive Cancer Network : JNCCN. 18:490-492. 2020
- Twin pregnancy with metastatic complete molar pregnancy and coexisting live fetus. Radiology Case Reports. 15:195-200. 2020
- Examining policy cohesion for cervical cancer worldwide: analysis of WHO country reports. ESMO Open. 5:e000878-e000878. 2020
- Treatment of first-void urine with Aptima Transfer Solution increases detection of high-risk HPV E6/E7 mRNA. Journal of Virological Methods. 267:48-52. 2019
- Current Quality of Gynecologic Cancer Care in North America. Obstetrics and Gynecology Clinics of North America. 46:1-17. 2019
- Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials. The Lancet Oncology. 19:1680-1687. 2018
- Venous Thromboembolic Events Following Major Pelvic and Abdominal Surgeries for Cancer: A Prospective Cohort Study. Annals of Surgical Oncology. 25:3214-3221. 2018
- Outcomes of Adjuvant Therapy for Stage IA Serous Endometrial Cancer. Cureus. 10:e3387. 2018
- Effect of Positron Emission Tomography Imaging in Women With Locally Advanced Cervical Cancer. JAMA network open. 1:e182081-e182081. 2018
- Cervical Cancer Screening in Low-Resource Settings. Journal of Obstetrics and Gynaecology Canada. 39:1183-1184. 2017
- Systemic Therapy for Recurrent Epithelial Ovarian Cancer: A Clinical Practice Guideline. Current Oncology. 24:540-546. 2017
- Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. 390:1949-1961. 2017
- A systematic review of patient values, preferences and expectations for the treatment of recurrent ovarian cancer. Gynecologic Oncology. 146:392-398. 2017
- Detection of cervical precancerous lesions with Aptima HPV assays using SurePath preservative fluid specimens. Tumour Virus Research. 3:155-159. 2017
- Genetics Consultation Rates Following a Diagnosis of High-Grade Serous Ovarian Carcinoma in the Canadian Province of Ontario. International Journal of Gynecological Cancer. 27:437-443. 2017
- The Added Value of Pathology Review in Vulvar Cancer: Results From a Population-based Cohort Study. International Journal of Gynecological Pathology. 36:107-110. 2017
- Does a groin node dissection in vulvar cancer affect groin recurrence and overall survival?: Results from a population-based cohort study. Gynecologic Oncology. 144:318-323. 2017
- Care Delivery Patterns, Processes, and Outcomes for Primary Ovarian Cancer Surgery: A Population-Based Review Using a National Administrative Database. Journal of Obstetrics and Gynaecology Canada. 39:25-33. 2017
- Follow-Up of Patients Who Are Clinically Disease-Free after Primary Treatment for Fallopian Tube, Primary Peritoneal, or Epithelial Ovarian Cancer: A Program in Evidence-Based Care Guideline Adaptation. Current Oncology. 23:343-350. 2016
- Cervical cancer screening in women over 65. PRO: Are we asking the right question?. Gynecologic Oncology. 142:381-382. 2016
- Follow-Up for Cervical Cancer: A Program in Evidence-Based Care Systematic Review and Clinical Practice Guideline Update. Current Oncology. 23:109-118. 2016
- Challenges in striving to simultaneously achieve multiple resource allocation goals: the pan-Canadian Oncology Drug Review (pCODR) example. Journal of Market Access and Health Policy. 4:31463-31463. 2016
- Comparing stage of diagnosis of cervical cancer at presentation in immigrant women and long-term residents of Ontario: a retrospective cohort study. CMAJ open. 4:E424-E430. 2016
- Patient, tumor, and health system factors affecting groin node dissection rates in vulvar carcinoma: A population-based cohort study. Gynecologic Oncology. 139:465-470. 2015
- Recommendations for Follow-up Care for Gynecologic Cancer Survivors. Obstetrics and Gynecology. 126:1207-1214. 2015
- Oncologists’ Perceptions of Recurrent Ovarian Cancer Patients’ Preference for Participation in Treatment Decision Making and Strategies for When and How to Involve Patients in This Process. International Journal of Gynecological Cancer. 25:1717-1723. 2015
- How oncologists communicate information to women with recurrent ovarian cancer in the context of treatment decision making in the medical encounter. Health Expectations. 18:1066-1080. 2015
- Trends over time in the use of laparoscopic hysterectomy for the treatment of endometrial cancer. Gynecologic Oncology. 138:536-541. 2015
- The Optimal Organization of Gynecologic Oncology Services: A Systematic Review. Current Oncology. 22:282-293. 2015
- The Organization of Colposcopy Services in Ontario: Recommended Framework. Current Oncology. 22:287-296. 2015
- The Silence in Hoch et al.’s Commentary about the Rationale for and Objective(s) of Canada’s Separate HTA Process for Cancer Drugs: The Importance of Transparency and Accountability when Allocating Taxpayers’ Dollars. PharmacoEconomics (Auckland). 33:883-886. 2015
- Systemic Therapy for Recurrent, Persistent, or Metastatic Cervical Cancer: A Clinical Practice Guideline. Current Oncology. 22:211-219. 2015
- Time Interval Between Endometrial Biopsy and Surgical Staging for Type I Endometrial Cancer. Obstetrics and Gynecology. 125:1497-1498. 2015
- An Organizational Guideline for Gynecologic Oncology Services. International Journal of Gynecological Cancer. 25:551-558. 2015
- UNDIFFERENTIATED ENDOMETRIAL CANCER, A DIFFERENT ENTITY WITH AN AGGRESSIVE BEHAVIOR. International Journal of Gynecological Cancer. 25:69-69. 2015
- Is There an Economic Rationale for Cancer Drugs to Have a Separate Reimbursement Review Process for Resource Allocation Purposes?. PharmacoEconomics (Auckland). 33:235-241. 2015
- Further Insights Into Long-Term Trends in Relative Survival of Vulvar Cancer Patients: A Population-Based Study. International Journal of Gynecological Cancer. 25:125-130. 2015
- Wait times from diagnosis to treatment in cancer. Journal of Gynecologic Oncology. 26:246-246. 2015
- Role of cervical screening in older women. Maturitas. 79:413-420. 2014
- Phase II study of oral ridaforolimus in women with recurrent or metastatic endometrial cancer. Gynecologic Oncology. 135:184-189. 2014
- Cervical Cancer Incidence in Ontario Women: Differing Sociodemographic Gradients by Morphologic Type (Adenocarcinoma Versus Squamous Cell). International Journal of Gynecological Cancer. 24:1341-1346. 2014
- Trends in incidence and survival of women with invasive vulvar cancer in the United States and Canada: A population-based study. Gynecologic Oncology. 134:314-318. 2014
- Cervical cancer in the older woman. Maturitas. 78:160-167. 2014
- Reply to J. Menczer. Journal of Clinical Oncology. 32:2114-2114. 2014
- Evaluation of a New APTIMA Specimen Collection and Transportation Kit for High-Risk Human Papillomavirus E6/E7 Messenger RNA in Cervical and Vaginal Samples. Sexually Transmitted Diseases. 41:365-368. 2014
- The association between cervical cancer screening and mortality from cervical cancer: A population based case–control study. Gynecologic Oncology. 133:167-171. 2014
- The Ethics of Engaged Presence: A Framework for Health Professionals in Humanitarian Assistance and Development Work. Developing World Bioethics. 14:47-55. 2014
- Management of advanced or recurrent cervical cancer: chemotherapy and beyond. Expert Review of Anticancer Therapy. 14:319-332. 2014
- Ease and Comfort of Cervical and Vaginal Sampling for Chlamydia trachomatis and Trichomonas vaginalis with a New Aptima Specimen Collection and Transportation Kit. Journal of Clinical Microbiology. 52:668-670. 2014
- Impact of Wait Times on Survival for Women With Uterine Cancer. Journal of Clinical Oncology. 32:27-33. 2014
- Clinical and toxicity predictors of response and progression to temsirolimus in women with recurrent or metastatic endometrial cancer. Gynecologic Oncology. 131:315-320. 2013
- The wait time creep: Changes in the surgical wait time for women with uterine cancer in Ontario, Canada, during 2000–2009. Gynecologic Oncology. 131:151-157. 2013
- Risks and benefits of screening asymptomatic women for ovarian cancer: A systematic review and meta-analysis. Gynecologic Oncology. 130:674-681. 2013
- Characterization of Androgenetic/Biparental Mosaic/Chimeric Conceptions, Including Those With a Molar Component. International Journal of Gynecological Pathology. 32:199-214. 2013
- Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial. The Lancet Oncology. 14:236-243. 2013
- International Gynecologic Cancer Society (IGCS 2012). Gynecologic Oncology. 128:12-14. 2013
- Palliative systemic therapy for women with recurrent epithelial ovarian cancer: current options. OncoTargets and Therapy. 6:107-107. 2013
- Sociodemographic factors associated with cervical cancer screening coverage and follow-up of high grade abnormal results in a population-based cohort. Gynecologic Oncology. 128:95-100. 2013
- The impact of prophylactic salpingo‐oophorectomy on quality of life and psychological distress in women with a BRCA mutation. Psycho-Oncology. 22:212-219. 2013
- Dalteparin Low Molecular Weight Heparin (LMWH) in ovarian cancer: A phase II randomized study. Thrombosis Research. 130:894-900. 2012
- Five-year trends in mortality indices among gynecological cancer patients in Canada. Gynecologic Oncology. 127:620-624. 2012
- The global cancer epidemic: opportunities for Canada in low- and middle-income countries. CANADIAN MEDICAL ASSOCIATION JOURNAL. 184:1699-1704. 2012
- Walking a tightrope: oncologists’ perspective on providing information to women with recurrent ovarian cancer (ROC) during the medical encounter. Supportive Care in Cancer. 20:2327-2333. 2012
- Cancer screening practices of cancer survivors: population-based, longitudinal study.. Canadian Family Physician. 58:980-986. 2012
- Temporal Trends in the Relative Survival Among Women With Cervical Cancer in Canada: A Population-Based Study. International Journal of Gynecological Cancer. 22:1208-1213. 2012
- Management of a Suspicious Adnexal Mass: A Clinical Practice Guideline. Current Oncology. 19:244-257. 2012
- Preoperative identification of a suspicious adnexal mass: A systematic review and meta-analysis. Gynecologic Oncology. 126:157-166. 2012
- Surgical management of a suspicious adnexal mass: A systematic review. Gynecologic Oncology. 126:149-156. 2012
- Trends in Gynecologic Cancer Care in North America. Obstetrics and Gynecology Clinics of North America. 39:107-129. 2012
- Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial. Annals of Oncology. 23:1185-1189. 2012
- Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial.. Annals of Oncology. 23:1185-1189. 2012
- Experience of Ethics Training and Support for Health Care Professionals in International Aid Work. Public Health Ethics. 5:91-99. 2012
- Models for Humanitarian Health Care Ethics. Public Health Ethics. 5:81-90. 2012
- Preface. Hand Clinics. 28:ix-ix. 2012
- Comparison of APTIMA HPV E6/E7 mRNA and Hybrid Capture 2 Assays using Wet and Dry Self-Collected Flocked Vaginal Swabs and PreservCyt L-Pap Samples. Journal of Analytical Oncology. 1:149-154. 2012
- Parental Knowledge, Attitudes, and Behaviours towards Human Papillomavirus Vaccination for Their Children: A Systematic Review from 2001 to 2011. Obstetrics and Gynecology International. 2012:1-12. 2012
- Sociodemographic factors associated with cervical cancer screening and follow-up of abnormal results.. Canadian Family Physician. 58:e22-e31. 2012
- Temsirolimus in combination with carboplatin and paclitaxel in patients with advanced solid tumors: a NCIC-CTG, phase I, open-label dose-escalation study (IND 179). Annals of Oncology. 23:238-244. 2012
- Temsirolimus in combination with carboplatin and paclitaxel in patients with advanced solid tumors: a NCIC-CTG, phase I, open-label dose-escalation study (IND 179).. Annals of Oncology. 23:238-244. 2012
- Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIG) CALYPSO sub-study. Annals of Oncology. 22:2417-2423. 2011
- Temporal trends in the relative survival among patients diagnosed with ovarian cancer in Canada 1992–2005: A population-based study. Gynecologic Oncology. 123:192-195. 2011
- Identifying population-level indicators to measure the quality of cancer care for women. International Journal for Quality in Health Care. 23:554-564. 2011
- Management of Women with Surgically Staged 1 Uterine Papillary Serous Cancer. ISRN Rehabilitation. 2011:1-9. 2011
- Phase II Study of Temsirolimus in Women With Recurrent or Metastatic Endometrial Cancer: A Trial of the NCIC Clinical Trials Group. Journal of Clinical Oncology. 29:3278-3285. 2011
- Ethical issues encountered by medical students during international health electives. Medical Education. 45:704-711. 2011
- Expectant management versus immediate treatment for low‐grade cervical intraepithelial neoplasia. Cancer. 117:1438-1445. 2011
- The impact of prophylactic salpingo-oophorectomy on menopausal symptoms and sexual function in women who carry a BRCA mutation. Gynecologic Oncology. 121:163-168. 2011
- Archivée: Prévention du cancer du col utérin au sein de milieux ne disposant que de faibles ressources. Journal of Obstetrics and Gynaecology Canada. 33:280-288. 2011
- RETIRED: Cervical Cancer Prevention in Low-Resource Settings. Journal of Obstetrics and Gynaecology Canada. 33:272-279. 2011
- Teaching cervical cancer surgery in low- or middle-resource countries.. International Journal of Gynecological Cancer. 20:1604-1608. 2010
- What we know about treatment decision making in ovarian cancer. Psicooncologia. 7:269-286. 2010
- Advanced Ovarian Cancer: Phase III Randomized Study of Sequential Cisplatin–Topotecan and Carboplatin–Paclitaxel vs Carboplatin–Paclitaxel. Journal of the National Cancer Institute. 102:1547-1556. 2010
- Ethics in Humanitarian Aid Work: Learning From the Narratives of Humanitarian Health Workers. AJOB Empirical Bioethics. 1:45-54. 2010
- End of life care for women with gynecologic cancers. Gynecologic Oncology. 118:196-201. 2010
- 'Playing God Because you Have to': Health Professionals' Narratives of Rationing Care in Humanitarian and Development Work. Public Health Ethics. 3:147-156. 2010
- Follow-Up for Women after Treatment for Cervical Cancer. Current Oncology. 17:65-69. 2010
- Sorafenib in Combination With Gemcitabine in Recurrent Epithelial Ovarian Cancer: A Study of the Princess Margaret Hospital Phase II Consortium. International Journal of Gynecological Cancer. 20:787-793. 2010
- A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: A trial of the Chicago, PMH, and California Phase II Consortia. Gynecologic Oncology. 117:37-40. 2010
- It's a choice to move forward: women's perceptions about treatment decision making in recurrent ovarian cancer. Psycho-Oncology. 19:318-325. 2010
- Malignant Transformation Within Ovarian Dermoid Cysts. International Journal of Gynecological Cancer. 20:75-81. 2010
- The Optimum Organization for the Delivery of Colposcopy Service in Ontario. Journal of Lower Genital Tract Disease. 14:11-21. 2010
- Follow-up for women after treatment for cervical cancer: A systematic review. Gynecologic Oncology. 114:528-535. 2009
- Who are the Providers of Gynaecologic Cancer Surgical Care in Ontario?. Journal of Obstetrics and Gynaecology Canada. 31:721-729. 2009
- Immunohistochemical localization of tyrosine receptor kinases A and B in endometriosis‐associated ovarian cancer. Histopathology. 54:907-912. 2009
- Secondary Cancer Prevention During Follow-up for Endometrial Cancer. Obstetrics and Gynecology. 113:790-795. 2009
- Breast and ovarian cancer risk perception after prophylactic salpingo‐oophorectomy due to an inherited mutation in the BRCA1 or BRCA2 gene. Clinical Genetics. 75:220-224. 2009
- Patterns of care for the initial management of cervical cancer in Ontario.. EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY. 30:493-496. 2009
- Patterns of care in the initial management of women with ovarian cancer in Ontario.. EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY. 30:361-364. 2009
- Patterns of care in the initial management of women with vulvar cancers in Ontario.. EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY. 30:503-505. 2009
- Patterns of surgical care for uterine cancers in Ontario.. EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY. 30:255-258. 2009
- Role of professional societies in the global battle against gynecologic cancers.. EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY. 30:605-608. 2009
- Surgical outcomes in women with ovarian cancer.. Canadian Journal of Surgery. 51:346-354. 2008
- Phase II Study of Erlotinib in Recurrent or Metastatic Endometrial Cancer: NCIC IND-148. Journal of Clinical Oncology. 26:4319-4325. 2008
- Human Papillomavirus DNA versus Papanicolaou Screening Tests for Cervical Cancer. New England Journal of Medicine. 358:641-644. 2008
- Reproducibility of the Histological Diagnosis of Cervical Dysplasia Among Pathologists From 4 Continents. International Journal of Gynecological Pathology. 27:101-107. 2008
- Optimal Chemotherapy Treatment for Women with Recurrent Ovarian Cancer. Current Oncology. 14:195-208. 2007
- Intraperitoneal chemotherapy for women with stage III epithelial ovarian cancer: Improving survival outcomes for patients. American Journal of Oncology Review. 6:459-464. 2007
- Use of systemic therapy in women with recurrent ovarian cancer—Development of a national clinical practice guideline. Gynecologic Oncology. 106:181-192. 2007
- A Tale of Two Time Periods: Ovarian Cancer Trends in Ontario. Current Oncology. 14:57-60. 2007
- Ontario Cervical Cancer Screening Clinical Practice Guidelines. Journal of Obstetrics and Gynaecology Canada. 29:344-353. 2007
- Intraperitoneal chemotherapy in the first‐line treatment of women with stage III epithelial ovarian cancer. Cancer. 109:692-702. 2007
- Chemotherapy for recurrent, metastatic, or persistent cervical cancer: a systematic review. International Journal of Gynecological Cancer. 17:1194-1204. 2007
- Clinical Management Recommendations for Surveillance and Risk-Reduction Strategies for Hereditary Breast and Ovarian Cancer Among Individuals Carrying a Deleterious BRCA1 or BRCA2 Mutation. Journal of Obstetrics and Gynaecology Canada. 29:45-60. 2007
- Colposcopists' agreement on cervical biopsy site.. Clinical and Experimental Obstetrics and Gynecology. 34:88-90. 2007
- Giving patients information on abnormal cytology and human papillomavirus: survey of health providers.. EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY. 28:15-17. 2007
- Outcomes for systemic therapy in women with ovarian cancer. Gynecologic Oncology. 103:554-558. 2006
- The Quality of the Operative Report for Women With Ovarian Cancer in Ontario. Journal of Obstetrics and Gynaecology Canada. 28:892-897. 2006
- Drug evaluation: AP-23573--an mTOR inhibitor for the treatment of cancer.. IDrugs: the Investigational Drugs Journal. 9:636-644. 2006
- Adjuvant radiotherapy in women with stage I endometrial cancer: A systematic review. Gynecologic Oncology. 102:361-368. 2006
- Follow-up after primary therapy for endometrial cancer: A systematic review. Gynecologic Oncology. 101:520-529. 2006
- Promoting Best Gynecologic Oncology Practice: A Role For The Society of Gynecologic Oncologists of Canada. Current Oncology. 13:94-98. 2006
- Prophylactic oophorectomy: When does it make sense?. Consultant. 46:647-648. 2006
- Assessment of 2 Cervical Screening Methods in Mongolia. Journal of Lower Genital Tract Disease. 10:83-88. 2006
- An analysis of alternative funding for physicians practicing gynecologic oncology in Ontario, Canada prior to 2001.. EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY. 27:61-64. 2006
- Does shifting a physician payment system shift physician priorities? A multi-site evaluation of an alternative payment plan (APP) for gynecologic oncologists in Ontario.. EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY. 27:375-378. 2006
- Physicians' attitudes, beliefs and knowledge concerning ovarian cancer.. EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY. 27:19-24. 2006
- Prognostic factors for women with Stage 1 ovarian cancer with or without adhesions.. EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY. 27:585-588. 2006
- Invasive vulvar cancer in a woman with human immunodeficiency virus: Case report and review of the literature. Gynecologic Oncology. 98:151-154. 2005
- Steppe by steppe: gynecological oncology on the Mongolian plains. International Journal of Gynecological Cancer. 15:359-360. 2005
- Evaluation of Postoperative Pain Control for Women Undergoing Surgery for Gynaecologic Malignancies. Journal of Obstetrics and Gynaecology Canada. 26:1051-1058. 2004
- Report of the 2003 Pan-Canadian Forum on Cervical Cancer Prevention and Control. Journal of Obstetrics and Gynaecology Canada. 26:1004-1014. 2004
- Systematic review of adjuvant care for women with Stage I ovarian carcinoma. Cancer. 101:1926-1935. 2004
- Screening Postmenopausal Women for Ovarian Cancer: A Systematic Review. Journal of Obstetrics and Gynaecology Canada. 26:717-728. 2004
- Job satisfaction, stress, and burnout among Canadian gynecologic oncologists. Gynecologic Oncology. 94:134-139. 2004
- Pitfalls in the Diagnosis of Cervical Intraepithelial Neoplasia 1. Journal of Lower Genital Tract Disease. 8:181-187. 2004
- Optimal management for surgically Stage 1 serous cancer of the uterus. Gynecologic Oncology. 92:240-246. 2004
- Surgery as sole treatment for serous borderline tumors of the ovary with noninvasive implants. Gynecologic Oncology. 90:407-412. 2003
- Erratum to “Women’s perceptions about treatment decision making for ovarian cancer”. Gynecologic Oncology. 90:232-232. 2003
- Phase II study of CGP 69846A (ISIS 5132) in recurrent epithelial ovarian cancer: an NCIC clinical trials group study (NCIC IND.116)☆. Gynecologic Oncology. 89:129-133. 2003
- Women’s perceptions about treatment decision making for ovarian cancer. Gynecologic Oncology. 88:89-95. 2003
- Outcomes in Surgery for Ovarian Cancer. Gynecologic Oncology. 87:260-267. 2002
- CCI-779 Wyeth.. Current Opinion in Investigational Drugs. 3:1249-1253. 2002
- Referral Patterns for Gynaecologic Cancers and Precancerous Conditions. Journal of Obstetrics and Gynaecology Canada. 24:553-558. 2002
- Concurrent Cisplatin-based Chemotherapy plus Radiotherapy for Cervical Cancer–a Meta-analysis. Clinical Oncology. 14:203-212. 2002
- A Comparison of Two Prophylactic Regimens for Hypersensitivity Reactions to Paclitaxel. Gynecologic Oncology. 84:420-425. 2002
- Current status and future innovations of hormonal agents, chemotherapy and investigational agents in endometrial cancer. Current Opinion in Obstetrics and Gynecology. 14:67-73. 2002
- Chemotherapy for recurrent epithelial ovarian cancer previously treated with platinum--a systematic review of the evidence from randomized trials.. EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY. 23:104-110. 2002
- Familial and hormonal risk factors for papillary serous uterine cancer.. EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY. 23:187-190. 2002
- Risk factors for ovarian cancer and early-onset breast cancer in Mongolia.. EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY. 23:397-400. 2002
- Adding cisplatin to ifosfamide may improve progression-free survival but greatly increases toxicity in women with carcinosarcoma of the uterus. Growth Hormone and IGF Research. 2:142-144. 2001
- Weekly Intravenous Methotrexate with Folinic Acid for Nonmetastatic Gestational Trophoblastic Neoplasia. Gynecologic Oncology. 82:367-370. 2001
- Cutaneous Metastasis of Papillary Serous Uterine Cancer. Gynecologic Oncology. 82:208-211. 2001
- A unique BRCA1 mutation identified in Mongolia. International Journal of Gynecological Cancer. 11:241-243. 2001
- Familial ovarian cancer.. Canadian Family Physician. 47:778-784. 2001
- Prophylactic oophorectomy in Ontario.. Familial Cancer. 1:143-148. 2001
- Quality of life and psychosexual adjustment after prophylactic oophorectomy for a family history of ovarian cancer.. Familial Cancer. 1:149-156. 2001
- Is Uterine Papillary Serous Adenocarcinoma a Manifestation of the Hereditary Breast–Ovarian Cancer Syndrome?. Gynecologic Oncology. 79:477-481. 2000
- Novel strategies for systemic treatment of endometrial cancer. Expert Opinion on Investigational Drugs. 9:2831-2853. 2000
- Endodermal Sinus Tumor in Pregnancy. Gynecologic Oncology. 78:265-266. 2000
- Reply. Gynecologic Oncology. 78:266-266. 2000
- Better Treatments That Cost More: The Dilemma. Gynecologic Oncology. 78:1-2. 2000
- Endometrial cancer. Prevention, detection, management, and follow up.. Canadian Family Physician. 46:887-892. 2000
- Hybrid Capture Human Papillomavirus Testing as an Adjunct to the Follow-Up of Patients with ASCUS and LGSIL Pap Smears: A Study of a Screening Population. Journal of Lower Genital Tract Disease. 4:12-17. 2000
- Use of topotecan in pre-treated recurrent or relapsed ovarian cancer patients. Current Oncology. 7:136-148. 2000
- Comparing the morbidity of single versus separate incision surgical approaches to vulvar cancer. Journal of Gynecologic Techniques. 5:147-150. 1999
- Preface. Computational and Theoretical Chemistry. 493:ix-ix. 1999
- Management of Colposcopy Patients with Biopsy-Proven Cervical Intraepithelial Neoplasia Grade 1. Journal of Lower Genital Tract Disease. 3:191-195. 1999
- An Endodermal Sinus Tumor Diagnosed in Pregnancy: Case Report and Review of the Literature. Gynecologic Oncology. 72:123-127. 1999
- Development of a Population Survey Concerning Papanicolaou Smear Screening for Cervical Disease. Journal of Lower Genital Tract Disease. 3:25-29. 1999
- Predictors of intention to act: High-school students and cervical screening. Current Oncology. 6:36-42. 1999
- Assessment of cytologic follow‐up as the recommended management for patients with atypical squamous cells of undetermined significance or low grade squamous intraepithelial lesions. Cancer. 84:5-10. 1998
- Economic and policy implications of adopting paclitaxel as first-line therapy for advanced ovarian cancer: an Ontario perspective.. Journal of Clinical Oncology. 15:632-639. 1997
- Patients’ Preferences for Therapy in Advanced Epithelial Ovarian Cancer: Development, Testing, and Application of a Bedside Decision Instrument. Gynecologic Oncology. 62:329-335. 1996
- High-dose methotrexate for gestational trophoblastic disease. ACOG Current Journal Review. 8:34. 1995
- High-Dose Methotrexate for Gestational Trophoblastic Disease. Obstetrical and Gynecological Survey. 50:192-193. 1995
- High-Dose Methotrexate for Gestational Trophoblastic Disease. Gynecologic Oncology. 54:282-287. 1994
- Preface. Journal of Structural Geology. 15:v-vi. 1993
- Combined analysis of cervical smears. Cytopathology, image cytometry and in situ hybridization.. Acta Cytologica. 37:373-378. 1993
- Delayed delivery of second twin: report of four cases and review of the literature.. Obstetrics and Gynecology. 79:260-263. 1992
- Flow cytometric assessment of DNA ploidy is a useful prognostic factor for patients with granulosa cell ovarian tumors. International Journal of Gynecological Cancer. 1:227-232. 1991
- Splenic cyst carcinoma presenting in pregnancy. American Journal of Hematology. 32:57-60. 1989
-
presentations